Remibrutinib
ATC L04AA60 · 8 markets · 9 records
AU 2 records · 2 strengths
- 25 mgtabletRHAPSIDO remibrutinib 25 mg tablet blister pack
Records without a stated strength · 1 RHAPSIDO
US 1 records · 1 strengths
- 25 mgtabletRHAPSIDO
GB 1 records · 1 strengths
- 25 mgtabletRHAPSIDO
CA 1 records · 1 strengths
- 25 mgtabletRHAPSIDO
TW 1 records · 1 strengths
- 25 mgtabletRHAPSIDO瑞喜多25毫克膜衣錠
HK 1 records · 1 strengths
Records without a stated strength · 1 RHAPSIDO
EU 1 records · 1 strengths
EU centralised authorisation (EMA) — Authorised at EU level — not a record of sale in any single country. The EU register carries no strength, dosage form or pack size.
Records without a stated strength · 1 RHAPSIDO
| Strength / form / release | US | GB | CA | AU | TW | HK | EU |
|---|---|---|---|---|---|---|---|
| 25 mg tablet | RHAPSIDO | RHAPSIDO | RHAPSIDO | RHAPSIDO remibrutinib 25 mg tablet blister pack | RHAPSIDO 瑞喜多25毫克膜衣錠 | ||
unknown | RHAPSIDO | RHAPSIDO | RHAPSIDO |
Scroll horizontally for more markets →
Each country column shows the locally registered trade names — not translations.
“not disclosed” means the source does not publish the strength — it does not mean the product has none.
Hong Kong records are name/ingredient-level only: no strength, dosage form or registration status; on the register does not prove current supply.
Australia ARTG data has no registration-status column, so status is shown as unknown; being on the register does not mean currently marketed.
EU centralised authorisation (EMA) — Authorised at EU level — not a record of sale in any single country. The EU register carries no strength, dosage form or pack size.
Discontinued, withdrawn or unverified-status products are hidden by default; Hong Kong and Australia records are shown as exceptions.